argenx SE ADR ARGX 深 沪
已收盘 10-31 16:00:00 美东时间
818.50
-1.860
-0.23%
华盛通- 最 高828.845
- 今 开828.845
- 成交量 40.29万股
- 最 低 805.02
- 昨 收 820.36
- 总市值 503.94亿
- 52周最高 855.46
- 市盈率 静 64.15
- 换手率 0.00%
- 52周最低 510.055
- 委 比 -86.92%
- 总股本 6156.89万
- 历史最高 855.46
- 量 比 0.90
- 振 幅 2.90%
- 历史最低 19.00
- 每 手 1
- 风险率 74.94%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For October 30, 2025
Companies Reporting Before The Bell • Altria Group (NYSE:MO) is projected to re...
10-30 19:12
argenx Q3 EPS $5.18 Beats $4.30 Estimate, Sales $1.151B Beat $1.056B Estimate
argenx (NASDAQ:ARGX) reported quarterly earnings of $5.18 per share which beat the analyst consensus estimate of $4.30 by 20.44 percent. This is a 272.66 percent increase over earnings of $1.39 per share from the same
10-30 14:03
Argenx SE Highlights VYVGART’s Efficacy in Treating Myasthenia Gravis
The latest announcement is out from Argenx Se ( ($ARGX) ). On October 29, 2025,...
10-29 23:27
argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients
VYVGART demonstrated efficacy and safety across diverse gMG populations, including AChR-Ab seronegative patients, with significant improvements in MG-ADL scores and steroid reduction.
10-29 15:00
Baron Health Care Fund buys ABBV, UNH, ROIV; exits WAT and COO
Baron Health Care Fund increased 5.39% in Q3 2025, compared with the 5.05% gain for the Russell 3000 Health Care Index and the 8.18% gain for the Russell 3000 Index. The fund outperformed by 9.30% on ...
10-29 02:19
If You Invested $1000 In argenx Stock 5 Years Ago, You Would Have This Much Today
argenx (NASDAQ:ARGX) has outperformed the market over the past 5 years by 11.18...
10-23 05:30
Argenx To Present VYVGART And Empasiprubart Data At AANEM Annual Meeting And MGFA Scientific Session In San Francisco
Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART's potential to treat broad set of myasthenia gravis patientsReal-world evidence and long-term data reinforce VYVGART's sustained impact on patient
10-15 13:11
argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session
argenx公司将展示VYVGART和empasiprubart在治疗重症肌无力、慢性炎性脱髓鞘性多发神经病、多灶性运动神经病和自身免疫性肌炎方面的临床数据。这些研究显示了VYVGART在不同患者群体中的潜在疗效，包括抗乙酰胆碱受体抗体阴性患者和青少年患者，同时 empasiprubart在CIDP和MMN的治疗中也显示出临床效果。 argenx公司展示了其治疗方法在治疗罕见神经肌肉疾病中的潜力。
10-15 05:00
美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
10-14 09:56
